scholarly journals Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy

2009 ◽  
Vol 106 (12) ◽  
pp. 4822-4827 ◽  
Author(s):  
L. S. Sasportas ◽  
R. Kasmieh ◽  
H. Wakimoto ◽  
S. Hingtgen ◽  
J. A. J. M. van de Water ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Cancer Therapy ◽  
Therapeutic Efficacy ◽  
Human Mesenchymal Stem Cells

scholarly journals Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Nari Shin ◽  
Namhee Jung ◽  
Seung-Eun Lee ◽  
Dasom Kong ◽  
Nam Gyo Kim ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Atopic Dermatitis ◽  
Therapeutic Efficacy ◽  
Nuclear Translocation ◽  
Human Mesenchymal Stem Cells ◽  
Mast Cell Activation ◽  
Regeneration Ability ◽  
Human Umbilical Cord ◽  
Widespread Application

Abstract Background Human mesenchymal stem cells (hMSCs) therapy has recently been considered a promising treatment for atopic dermatitis (AD) due to their immunomodulation and tissue regeneration ability. In our previous studies, we demonstrated that hMSCs alleviate allergic inflammation in murine AD model by inhibiting the activation of mast cells and B cells. Also our phase I/IIa clinical trial showed clinical efficacy and safety of hMSCs in moderate-to-severe adult AD patients. However, hMSCs therapy against atopic dermatitis have had poor results in clinical field. Therefore, we investigated the reason behind this result. We hypothesized that drug–cell interaction could interfere with the therapeutic efficacy of stem cells, and investigated whether coadministration with pimecrolimus, one of the topical calcineurin inhibitors, could influence the therapeutic potential of human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) in AD. Methods hUCB-MSCs were subcutaneously injected to AD-induced mice with or without pimecrolimus topical application. To examine whether pimecrolimus influenced the immunomodulatory activity of hUCB-MSCs, hUCB-MSCs were treated with pimecrolimus. Results Pimecrolimus disturbed the therapeutic effect of hUCB-MSCs when they were co-administered in murine AD model. Moreover, the inhibitory functions of hUCB-MSCs against type 2 helper T (Th2) cell differentiation and mast cell activation were also deteriorated by pimecrolimus treatment. Interestingly, we found that pimecrolimus decreased the production of PGE2, one of the most critical immunomodulatory factors in hUCB-MSCs. And we demonstrated that pimecrolimus downregulated COX2-PGE2 axis by inhibiting nuclear translocation of NFAT3. Conclusions Coadministration of pimecrolimus with hMSCs could interfere with the therapeutic efficacy of hMSCs in atopic dermatitis, and this is the first study that figured out the interaction of hMSCs with other drugs in cell therapy of atopic dermatitis. Therefore, this study might give rise to improvement of the clinical application of hMSCs therapy and facilitate the widespread application of hMSCs in clinical field.

Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy

2010 ◽  
Vol 10 (4) ◽  
pp. 411-421 ◽  
Author(s):  
S. Cruet-Hennequart ◽  
A.M. Prendergast ◽  
F.P. Barry ◽  
M.P. Carty
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Cancer Therapy ◽  
Human Mesenchymal Stem Cells ◽  
Dna Damaging Agents

Proliferation and multi-differentiation potentials of human mesenchymal stem cells on thermoresponsive PDMS surfaces grafted with PNIPAAm

2010 ◽  
Vol 30 (6) ◽  
pp. 455-455 ◽  
Author(s):  
Dongyan Shi ◽  
Dan Ma ◽  
Feiqing Dong ◽  
Chen Zong ◽  
Liyue Liu ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Human Mesenchymal Stem Cells

The Effect of Link N on the Differentiation of Human Mesenchymal Stem Cells

2012 ◽  
Vol 2 (1_suppl) ◽  
pp. s-0032-1320001-s-0032-1320001
Author(s):  
F. Mwale ◽  
H. T. Wang ◽  
L. Haglund ◽  
P. J. Roughley ◽  
J. Antoniou
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Human Mesenchymal Stem Cells

Generation of human mesenchymal stem cells lacking diabetoporosity-associated miRNAs using CRISPR/Cas9

2020 ◽  
Author(s):  
I Foessl ◽  
A Groselj-Strele ◽  
JC Piswanger-Sölkner ◽  
H Dobnig ◽  
A Fahrleitner-Pammer ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Human Mesenchymal Stem Cells
Sign in / Sign up

Export Citation Format

Share Document